.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,129,933

« Back to Dashboard

Details for Patent: 6,129,933

Title: Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
Abstract:A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.
Inventor(s): Oshlack; Benjamin (New York, NY), Chasin; Mark (Manalapan, NJ), Pedi, Jr.; Frank (Yorktown Heights, NY)
Assignee: Purdue Pharma LP (Norwalk, CT)
Filing Date:Jul 24, 1997
Application Number:08/899,924
Claims:1. An oral controlled release pharmaceutical formulation comprising

a plurality of inert beads coated with an analgesic, said inert beads incorporated into said formulation in a therapeutically effective amount

a barrier layer over said beads coated with said analgesic, said barrier layer comprising hydroxypropylmethylcellulose,

a controlled release layer over said barrier layer comprising an aqueous dispersion of plasticized ethylcellulose in an amount sufficient to obtain a controlled release of said analgesic when said formulation is exposed to an environmental fluid, said controlled release layered beads being cured to a temperature greater than the glass transition temperature of the aqueous dispersion of the plasticized ethylcellulose for at least about 24 hours.

2. The formulation of claim 1, wherein said barrier layered beads are coated to a weight gain from about 2 to about 30% with said controlled release layer.

3. The formulation of claim 1, wherein a plurality of said coated, cured beads are placed in a capsule in an amount sufficient to provide an effective controlled release of said analgesic when contacted by an environmental fluid.

4. The formulation of claim 1, further comprising a second barrier layer over said controlled release layer, said second barrier layer comprising hydroxypropylmethylcellulose.

5. The formulation of claim 1, wherein said controlled release layer further comprises a release-modifying agent in an amount effective to modify the rate of release of said analgesic from said cured, coated substrate.

6. The formulation of claim 5, wherein said release-modifying agent is selected from the group consisting of a hydrophilic polymer, a semi-permeable polymer, an erosion-promoting polymer, an agent capable of making microporous lamina, a poreformer and mixtures of any of the foregoing.

7. The formulation of claim 6, wherein said controlled release layer comprises from about 0.1% to about 70% of said release-modifying agent.

8. The formulation of claim 7, wherein said release-modifying agent is selected from the group consisting of hydroxypropylmethylcellulose, lactose, metal stearates and mixtures of any of the foregoing.

9. The formulation of claim 1, wherein a portion of the amount of said analgesic included in said formulation is incorporated into an outer coating.

10. A method for preparing an oral controlled release formulation of an analgesic, comprising:

coating pharmaceutically acceptable inert beads with an analgesic;

thereafter coating said beads with a barrier layer comprising hydroxypropylmethylcellulose;

thereafter applying a controlled release layer onto said beads, said controlled release layer comprising a sufficient amount of a plasticized ethylcellulose to obtain a predetermined controlled release of said analgesic when said coated beads are exposed to an environmental fluid, said plasticized ethylcellulose being applied to said beads as an aqueous dispersion; and

curing said controlled release layered beads at a temperature greater than the glass transition temperature of the aqueous dispersion of plasticized ethylcellulose for at least 24 hours.

11. The method of claim 10, further comprising placing a sufficient quantity of cured coated beads into a gelatin capsule.

12. The method of claim 10, further comprising coating said controlled release beads with an outer layer comprising said analgesic.

13. The method of claim 10, wherein said barrier layer comprises hydroxypropylmethylcellulose.

14. The method of claim 10, further comprising applying said controlled release layer onto said beads to a weight gain from about 2 to about 25%.

15. The method of claim 10, further comprising adding a release-modifying agent to said controlled release layer in an amount effective to modify the rate of release of said analgesic from said cured, coated beads.

16. The method of claim 15, wherein said release-modifying agent is selected from the group consisting of a hydrophilic polymer, a semi-permeable polymer, an erosion-promoting polymer, an agent capable of making microporous lamina, a pore-former, and mixtures of any of the foregoing.

17. The method of claim 16, wherein said controlled release layer comprises from about 0.1% to about 70% of said release-modifying agent.

18. The method of claim 17, wherein said controlled release layer comprises from about 0.1% to about 50% of said release-modifying agent.

19. The method of claim 18, wherein said controlled release layer comprises from about 0.1% to about 25% of said release-modifying agent.

20. The method of claim 15, wherein said release-modifying agent is selected from the group consisting of hydroxypropylmethylcellulose, lactose, metal stearates, and mixtures of any of the foregoing.

21. The method of claim 10, further comprising overcoating said controlled release beads with a second barrier layer comprising hydroxypropylmethylcellulose.

22. The method of claim 10, further comprising the step of overcoating said controlled release beads with an outer layer comprising said analgesic.

23. The method of claim 21, further comprising the step of placing a sufficient quantity of said overcoated controlled release beads into a gelatin capsule.

24. The method of claim 22, wherein said outer layer comprises hydroxypropylmethylcellulose.

25. A controlled release formulation, comprising a plurality of pharmaceutically acceptable inert beads coated with an analgesic, said formulation comprising a therapeutically effective amount of said analgesic when said formulation is orally administered to a patient, said beads coated with said analgesic being overcoated with a barrier layer comprising hydroxypropylmethylcellulose, said barrier coated beads being coated with a controlled release layer of plasticized ethylcellulose in an amount sufficient to obtain a controlled release of said analgesic when said formulation is exposed to a gastrointestinal fluid, said ethylcellulose being applied to said beads as an aqueous dispersion, said coated beads being cured at a temperature greater than the glass transition temperature of the aqueous dispersion of plasticized ethylcellulose for at least about 24 hours, to cause individual ethylcellulose particles in said coating to coalesce and to gradually slow the release of said analgesic when said formulation is exposed to aqueous fluid, until an endpoint is reached at which said cured coated beads, when subjected to in-vitro dissolution, releases said analgesic in amounts which do not vary at any time point along the dissolution curve by more than about 20% of the total amount of analgesic released, when compared to the in-vitro dissolution of said coated beads prior to curing.

26. The formulation of claim 25, wherein said cured, coated beads provide the same rate of release immediately after curing to said endpoint, and after subsequent exposure to accelerated storage conditions of one month at a temperature of 37.degree. C. and at a relative humidity of 80%.

27. The formulation of claim 25, wherein said cured, coated beads provide the same rate of release immediately after curing to said endpoint, and after subsequent exposure to accelerated storage conditions of one month at a temperature of 40.degree. C. and at a relative humidity of 75%.

28. The formulation of claim 25, wherein said controlled release layer is applied on said barrier coated beads to a weight gain from about 2% to about 25%.

29. The formulation of claim 25, wherein a plurality of said coated, cured beads are placed in a capsule in an amount sufficient to provide an effective controlled release dose when contacted by an environmental fluid.

30. The formulation of claim 25, wherein said cured, coated formulation when administered orally provides effective blood levels of said analgesic for about 24 hours.

31. The formulation of claim 25, which includes a controlled release layer sufficient to obtain a controlled release of said analgesic when measured by the USP Paddle Method of U.S. Pharmacopeia XXII (1990) at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37.degree. C. from about 12.5% to about 42.5% (by wt) analgesic released after 1 hour, from about 25% to about 55% (by wt) analgesic released after 2 hours, from about 45% to about 75% (by wt) analgesic released after 4 hours and from about 55% to about 85% (by wt) analgesic released after 8 hours.

32. The formulation of claim 25, wherein said controlled release layer further comprises a release-modifying agent in an amount effective to modify the rate of release of said analgesic from said cured, coated substrate.

33. The formulation of claim 32, wherein said release-modifying agent is selected from the group consisting of a hydrophilic polymer, a semi-permeable polymer, an erosion-promoting polymer, an agent capable of making microporous lamina, a poreformer and mixtures of any of the foregoing.

34. The formulation of claim 25, which provides therapeutically effective blood levels of said analgesic when administered orally for about 12 hours.

35. The formulation of claim 25, wherein said analgesic is morphine.

36. The formulation of claim 25, further comprising a second barrier layer overcoated on said controlled release layer.

37. The formulation of claim 36, wherein said second barrier layer comprises hydroxypropylmethylcellulose.

38. The formulation of claim 37, further comprising an outer coating comprising a loading dose of said analgesic.

39. The formulation of claim 36, further comprising said overcoated controlled release beads in a gelatin capsule.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc